- Anniversary/History
- Membership
- Publications
- Resources
- Education
- Events
- Outreach
- Careers
- About
- For Pain Patients and Professionals
Gut microbiota has been reported to protect from lung viral infection in animal models by stimulating type-I interferon signaling. Type-I interferons can have direct antiviral activity while also stimulating antibody-producing B cells. Antibodies against Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV2) have been correlated to faster infection clearance and protection against reinfection. A specific 4-strain probiotic combination (Pediococcus acidilactici CECT7483 plus Lactoplantibacillus plantarum CECT7484, CECT7485 and CECT30292) was recently studied in a randomized, quadruple-blinded, placebo-controlled trial in 300 SARS-CoV2-infected, symptomatic ambulatory patients (NCT04517422). Study subjects did not receive corticosteroids or antivirals. Compared to placebo, probiotic intervention (2×10 cfu/day for 30 days) achieved faster symptom clearance and increased SARS-CoV2-specific immunoglobulins M and G (IgM and IgG). We hypothesize these effects could be related to increased type-I interferon signaling.